As of January, a decision will take effect that will significantly improve first-line treatment options for plasmocytic myeloma. However, this raises reimbursement challenges for patients with relapsed disease. The most pressing need is to include the KDd regimen in second-line reimbursement.
From the beginning of the year, daratumumab, which was previously reimbursed in the dara-VTD regimen for patients eligible for transplantation now, will also be available in the daratumumab-lenalidomide-dexamethasone, or dRD, regimen for patients ineligible for transplantation. In practice, this means covering the entire population with a very modern, standards-compliant treatment.
- Such reimbursement decisions force the next ones to be made in a while, regarding reimbursement of regimens in subsequent lines of treatment. We can already see that a major challenge will be the patients who will receive lenal...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
